Inloggad som:
IMCODE004
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
IMCODE004
En randomiserad, dubbelblind, multicenterstudie i fas II som utvärderar effekt och säkerhet för autogene cevumeran plus nivolumab, jämfört med nivolumab, som adjuvant behandling av patienter med högrisk muskelinvasiv urotelial cancer
A RANDOMIZED PHASE II, DOUBLE-BLIND, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF AUTOGENE CEVUMERAN PLUS NIVOLUMAB VERSUS NIVOLUMAB AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
PLACEHOLDER
A RANDOMIZED PHASE II, DOUBLE-BLIND, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF AUTOGENE CEVUMERAN PLUS NIVOLUMAB VERSUS NIVOLUMAB AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
Mer information om studien för vårdgivare
For patients identified prior to radical surgical resection, muscle-invasive UC of the bladder identified based on computed tomography (CT) or magnetic resonance imaging (MRI) scan of the pelvis, abdomen, and chest as cT3-T4 or N . Medically eligible for radical cystectomy and pelvic -forts se länk
Partial cystectomy in the setting of bladder cancer primary tumor or partial nephroureterectomy in the setting of renal pelvis primary tumor. Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment -forts se länk
Behandling
Fas 2
Prevention
Företag
Studien ändrades senast av: Mirella Wahl (2024-12-17)